NX Prenatal Appoints Leading Experts to Medical/Clinical Advisory Board; Company’s First Product Will Be Exosome-Based Blood Test to Stratify Risk of Preterm Birth

In a January 19, 2017 press release, NX Prenatal, Inc. announced the formation of its Medical/Clinical Advisory Board. This new board brings together leading clinicians and industry veterans who enhance the range and depth of expertise of the company as it accelerates development of its novel prenatal diagnostic tests. These experts are uniquely positioned to provide medical, clinical, and strategic guidance for the company's product development and commercialization activities. The first product will be a novel exosome-based blood test designed to stratify the risk of preterm birth in women as early as 10-12 weeks of pregnancy to provide physicians with a new decision support tool. Gail Page, NX Prenatal's Executive Chairperson, added, "We are pleased to be surrounded by advisors who have deep knowledge in the fields of maternal fetal medicine, obstetrics, proteomics, and biomarker test commercialization. We recognize the importance of working closely with key opinion leaders to ensure that our diagnostic tests are relevant and address an unmet need in the clinical community that will use them." The advisory board members include the following: KEVIN ROSENBLATT, M.D., PH.D. (CHAIR) Dr. Rosenblatt is Chief Medical & Scientific Officer of NX Prenatal. He previously served as CMO/CSO of CompanionDx Labs, a precision medicine/diagnostics company. Dr. Rosenblatt is recognized internationally for his proteomics and genomics expertise and has published over 60 papers on biomarker development and clinical proteomics. He served as an Associate Professor in the Division of Oncology, Department of Internal Medicine, Associate Professor at the Brown Foundation Institute of Molecular Medicine and as Director of the Proteomics Core for the Center for Clinical and Translational Sciences at UT Health.
Login Or Register To Read Full Story